Yu, Z., Liu, W., Wang, L., Liang, H., Huang, Y., Si, X., … Zhang, H. (2009). The efficacy and safety of palonosetron compared with granisetron in preventing highly emetogenic chemotherapy-induced vomiting in the Chinese cancer patients: A phase II, multicenter, randomized, double-blind, parallel, comparative clinical trial. Supportive Care in Cancer, 17, 99–102.
To evaluate the safety and efficacy of palonosetron versus granisetron for prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving emetogenic chemotherapy
Patients were randomly assigned to receive a single IV dose of either palonosetron 0.25 mg or granisetron 3 mg as a bolus dose, 30 minutes before receiving chemotherapy. Patients were evaluated daily from study days 1–7, and investigators were responsible for recording emetic episodes, rescue medication, and adverse events. Complete response was defined as no emetic episodes and no rescue medication for the first 24-hour interval after chemotherapy and during successive 24-hour time periods.
The study was conducted at multiple sites in China.
All patients were in active treatment.
This was a double-blind, randomized, parallel comparative study.
Evaluation was based on the World Health Organization's evaluation criteria of emesis. Emetic episodes and use of rescue medication were recorded.
Palonosetron and granisetron appeared to provide similar results in control of CINV in the immediate, acute phase.